tiprankstipranks
Tryptamine Therapeutics Advances Clinical Trials
Company Announcements

Tryptamine Therapeutics Advances Clinical Trials

Story Highlights

Tryptamine Therapeutics (AU:TYP) has released an update.

Don't Miss Our Christmas Offers:

Tryptamine Therapeutics, a clinical-stage biotech company, has altered its reporting status in Canada to a ‘designated foreign issuer’ while continuing to meet Australian regulatory requirements. The company has successfully completed Phase 2a clinical trials for binge eating disorder and fibromyalgia and is advancing trials on a proprietary IV-infused psilocin treatment designed to improve patient outcomes.

For further insights into AU:TYP stock, check out TipRanks’ Stock Analysis page.

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App